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Burkholderia pseudomallei is the causative agent of melioidosis, a rare disease of biode-
fense concern with high mortality and extreme difficulty in treatment. No human vaccines
are available that protect against B. pseudomallei infection, and with the current limitations
of antibiotic treatment, the development of new preventative and therapeutic interventions
is crucial. Although clinical trials could be used to test the efficacy of new medical counter-
measures (MCMs), the high mortality rates associated with melioidosis raises significant
ethical issues concerning treating individuals with new compounds with unknown effica-
cies.The US Food and Drug Administration (FDA) has formulated a set of guidelines for the
licensure of new MCMs to treat diseases in which it would be unethical to test the efficacy
of these drugs in humans. The FDA “Animal Rule” 21 CFR 314 calls for consistent, well-
characterized B. pseudomallei strains to be used as challenge material in animal models. In
order to facilitate the efficacy testing of new MCMs for melioidosis using animal models,
we intend to develop a well-characterized panel of strains for use.This panel will comprise
of strains that were isolated from human cases, have a low passage history, are virulent
in animal models, and are well-characterized phenotypically and genotypically. We have
reviewed published and unpublished data on various B. pseudomallei strains to establish
an objective method for selecting the strains to be included in the panel of B. pseudomallei
strains with attention to five categories: animal infection models, genetic characterization,
clinical and passage history, and availability of the strain to the research community. We
identified 109 strains with data in at least one of the five categories, scored each strain
based on the gathered data and identified six strains as candidate for a B. pseudomallei
strain panel.
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INTRODUCTION
Burkholderia pseudomallei is a Gram-negative bacterial pathogen
responsible for the disease melioidosis, which is endemic in South-
east Asia, and northern Australia. B. pseudomallei can be cultured
from tropical soils without requiring a host for environmental
persistence (Kaestli et al., 2009; Currie et al., 2010). Melioidosis
is historically associated with a high mortality rate due to the
speed with which septicemia develops and the inherent resis-
tance of the bacteria to several classes of antibiotics. While the
overall mortality rate of melioidosis is 50% in Thailand, it is
only 19% in the endemic areas of Australia (Limmathurotsakul
et al., 2010). The difference between the mortality rates is most
likely a result of the differing availability of efficacious treatment,
though pathogen strain and host population differences may play
a role. Although prolonged courses of antibiotic treatment (at least
10 days of intravenous antibiotics, followed by 12–20 weeks of oral
antibiotics) are recommended, recurrent disease is common (at a
rate of ≥6% in the first year; Chaowagul et al., 1993; Currie et al.,
2000).
In addition to naturally occurring infections, B. pseudomallei
is considered a biodefense threat because of the ease of acquiring
strains from the environment, the ability to genetically manipu-
late the agent to be multiply antibiotic resistant, and the lack of a
melioidosis vaccine (Vietri and Deshazer, 2007). Given the lengthy
treatment with suboptimal outcomes, there is significant inter-
est in developing improved medical countermeasures (MCMs)
against melioidosis. In addition to improved antibiotic treatments,
licensed vaccines are not currently available for melioidosis pro-
phylaxis. In the case of B. pseudomallei, the limited number of
confirmed respiratory acquired melioidosis cases each year call
into question the feasibility of clinical trials for proper evaluation
of therapeutics and/or vaccines. Experimental infection of humans
with B. pseudomallei creates ethical concerns because therapeutic
options are limited and consist of lengthy regimens. If melioidosis
animal models are to be used to license new MCMs under the Food
and Drug Administration (FDA) Animal Rule, well-characterized
B. pseudomallei sources will be needed by the testing commu-
nity. Since a number of different B. pseudomallei strains have been
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used in a variety of animal models, comparisons of the data are
difficult. We reviewed the publicly available literature and used
personal communications to gather data relevant to strain source,
passage history, virulence, genotype, phenotype, and availability of
B. pseudomallei strains with focus on those. Additionally, attrib-
utes of B. pseudomallei strains which apply to the FDA Animal
Rule, particularly, animal infection models, genetic characteriza-
tion, clinical and passage history, and the availability of strains
to the research community were considered. FDA Animal Rule
draft guidance from 2009 states “the challenge agent used in ani-
mal studies generally should be identical to the etiologic agent
that causes the human disease (FDA, 2009).” For melioidosis, the
agent is B. pseudomallei, but many different strains have been iso-
lated from human cases. The genetic plasticity of B. pseudomallei
dictates that strains with well-documented and low numbers of
passages are preferred (Holden et al., 2004). Further, B. pseudoma-
llei is known to have an unstable genome and having a reference
genome sequence is desirable to monitor any genetic mutation and
drift that may occur from laboratory passages. The FDA Animal
Rule draft guidance also states“The disease manifestations, includ-
ing the outcome (morbidity or mortality), should be compared
between untreated animals and untreated humans (FDA, 2009).”
Since melioidosis is a lethal disease, we also examined lethality in
the animal model literature. Finally, as the development of animal
models and MCMs will be an effort spanning multiple laborato-
ries, we were interested in those B. pseudomallei strains that had
the fewest impediments to wide distribution, such as licenses or
restrictive material transfer agreements. We developed a scoring
matrix to select six strains for inclusion in a panel to be tested in
animal model development to meet the criteria of the FDA Animal
Rule. Ideally, bacterial challenge material used in efficacy studies
under the FDA Animal Rule would be a strain of B. pseudomallei
that was recently isolated from a lethal human case of inhalational
melioidosis, possess limited passage, exhibit virulence in one or
more animal model of melioidosis, be well-characterized, and be
freely available to laboratories licensed to work with B. pseudoma-
llei. Using these and other criteria, a ranking system was developed
and used to identify strains that will be included in a B. pseudo-
mallei reference panel. Each section of this review will focus on B.
pseudomallei strains that had the highest score for a single crite-
rion, based on the availability of information for that criterion.
ISOLATION AND PASSAGE HISTORY
We had two criteria associated with the strain history; the patient
history associated with the isolate and documented laboratory pas-
sage history. For isolation, strains were assigned a score on a scale
of zero through five using the following six criteria:
0 points for no data on isolation
1 point for environmental isolate
2 points for isolation from an animal infection
3 points for isolation from a human clinical case, with no other
data available
4 points for isolation from a human clinical case without
pulmonary presentation
5 points for isolation from a human case with pulmonary
presentation.
Using the above scoring matrix, three strains were assigned the
highest score of 5 (isolated from an acute human case with pul-
monary presentation, Table 1). Strain S141 was isolated in Ubon
Ratchathani, NE, Thailand from a 73-year-old male patient with
pneumonia. Strain 1710a was isolated from the blood culture in
1996 from a 52-year-old male rice farmer with a new diagnosis of
diabetes mellitus presenting to Sappasithiprasong Hospital, Ubon
Ratchathani, NE, Thailand (http://pathema.jcvi.breakorg/cgi-
bin/Burkholderia/shared/HtmlPage.cgi?page=strains). The patient
had disseminated disease, including bacteremia, lung involve-
ment, and soft tissue involvement. The patient survived to dis-
charge, but was readmitted in 1999 and died 1 day after readmis-
sion (http://pathema.jcvi.org/cgi-bin/Burkholderia/shared/Html
Page.cgi?page=strains). Strain 406e was isolated from a toe swab in
1988 from a 21-year-old male laborer presenting to Sappasithipra-
song Hospital (http://pathema.jcvi.org/cgi-bin/Burkholderia/
shared/HtmlPage.cgi?page=strains). The patient had dissemi-
nated disease including bacteremia, lung, skin, and renal tract
involvement. The patient succumbed to infection on the second
day of admission (http://pathema.jcvi.org/cgi-bin/Burkholderia/
shared/HtmlPage.cgi?page=strains; M. Wolcott, personal commu-
nication).
With only three strains receiving the highest score, other
strains that did not score as highly are included because of
other qualities making them attractive for animal model research.
Strain K96243 was isolated from a 34-year-old female dia-
betic patient in Thailand. Strain 1106a was isolated from a
23-year-old female rice farmer in Thailand in 1996. Strain
1106b was isolated from the liver abscess in 1996 from the
same rice farmer from which strain 1106a was isolated. Strain
MSHR305 was isolated from an autopsy sample from the brain
of a melioidosis encephalomyelitis case at the Royal Darwin
Hospital, Northern Territory, Australia (http://pathema.jcvi.org/
cgi-bin/Burkholderia/shared/HtmlPage.cgi?page=strains). Strain
MSHR668 was isolated from the blood culture of a 53-year-
old male patient with severe melioidosis encephalomyelitis at
the Royal Darwin Hospital in 1995. The patient required
prolonged ventilation, but survived. Strain 1026b was iso-
lated from blood culture in 1993 from 29-year-old female
rice farmer with a known diagnosis of diabetes melli-
tus presenting to Sappasithiprasong Hospital. The patient
had disseminated disease including bacteremia, soft tissue,
joint, and splenic involvement (http://pathema.jcvi.org/cgi-bin/
Burkholderia/shared/HtmlPage.cgi?page=strains).
The second criterion is passage history. Strains with the
lowest number of passages from clinical isolation were given
the highest scores. Due to the genetic plasticity of B. pseudo-
mallei, passage on artificial media or through animals could
readily select for genetic variants with unknown impact on
pathogenicity (Ulett et al., 2001), complicating data compar-
isons from studies using different sources of B. pseudomallei
with different or unknown passage histories. Therefore, avail-
able B. pseudomallei strains were assigned scores based on the
number of passages from isolation. High scoring B. pseudo-
mallei strains are shown in Table 2. Strains were assigned a
score on a scale of zero through five using the following six
criteria:
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Table 1 | Burkholderia pseudomallei strains with well described clinical isolations.
Bacterial
strain
Date of
isolation
Country of
origin
Clinical history Isolation
score
1710a 1996 Thailand 52-Year-old male rice farmer presenting to Sappasithiprasong Hospital, Ubon Ratchathani, NE,
Thailand
5
S141 Unknown Thailand Isolated in Ubon Thailand from a 73-year-old male patient with pneumonia 5
406e 1988 Thailand Toe swab isolated from a 21-year-old male laborer with disseminated disease including
bacteremia, lung, skin, and renal tract involvement
5
MSHR305 Unknown Australia This strain was isolated from an autopsy sample from the brain of a fatal melioidosis
encephalomyelitis case at the Royal Darwin Hospital, Northern Territory, Australia
4
1106a 1993 Thailand 23-Year-old female rice farmer presenting to Sappasithiprasong Hospital 4
1106b 1996 Thailand Pus aspirated from liver abscess in 1996 from patient described above (strain 1106a) 4
MSHR1655 2003 Australia Menzies School of Health Research. Sputum isolate from a 64-year-old Darwin female patient
treated at Royal Darwin Hospital
4
1710b 1999 Thailand Blood culture in march 1999 from patient described above (strain 1710a) 4
576a 1989 Thailand Blood culture from a 50-year-old female rice farmer presenting to Sappasithiprasong Hospital 4
B7210 1970 Australia Isolated from empyema drain in human in Australia 4
DL2 2006 Thailand Isolated from a fatal sepsis melioidosis case in Ubon, Thailand 4
DL25 2006 Thailand Isolated from a fatal sepsis melioidosis case in Ubon, Thailand 4
DL28 2006 Thailand Isolated from a fatal sepsis melioidosis case in Ubon, Thailand 4
DL35 2006 Thailand Isolated from a sepsis melioidosis case in Ubon, Thailand. Patient survived 4
DL36 2006 Thailand Isolated from a fatal sepsis melioidosis case in Ubon, Thailand 4
K96243 1996 Thailand Isolated from a 34-year-old female diabetic patient at Khon Kaen Hospital, northeast Thailand
with a clinical history of short incubation, septicemic infection, and rapid progression to death
4
MSHR487 Unknown Australia Isolated from a chronic melioidosis case. The patient was not very sick at all for several years 4
MSHR668 1995 Australia From Menzies School of Health Research. Blood culture isolate from a 53-year-old male patient
from Darwin with severe melioidosis encephalomyelitis
4
MSHR730 Unknown Australia Isolated from a melioidosis patient who had a chronic lung disease. The patient was not very sick
at all and got better quickly
4
MSHR840 1999 Australia Isolated from a fatal sepsis melioidosis case with risk factors. The patient lived in Queensland,
Australia
4
PB08298010 2009 USA Isolated from a severe melioidosis case in SE Arizona; patient had no foreign travel history 4
S191 Unknown Thailand Isolated from a 4-year-old, male, melioidosis patient who had parotid disease; patient survived 4
S241 Unknown Thailand Isolated from a 60-year-old, male, melioidosis patient who had parotid disease; patient survived 4
S90 Unknown Thailand Isolated from 1-month-old female infant who had septicemia and CNS involvement. The patient
was survived to discharge
4
1026b 1993 Thailand Blood from 29-year-old female rice farmer with diabetes mellitus and disseminated disease
including bacteremia, soft tissue, joint, and splenic involvement; survived to discharge
4
0 points for no passage data
1 point for >11 passages since isolation
2 points for 9–10 passages since isolation
3 points for 7–8 passages since isolation
4 points for 4–6 passages since isolation
5 points for 3 or fewer passages since isolation.
No strain was identified with 3 or fewer passages from iso-
lation, although strains passaged as few as 6 times were identi-
fied.
ANIMAL INFECTION MODELS
Strains selected for this reference panel should have a low lethal
dose with aerosol delivery in animal models for testing biodefense
MCMs. As mentioned above, the ideal etiologic agent for an FDA
Animal Rule study will cause lethality in both animals and humans
in an acute manner. For the purposes of this review, we considered
acute lethality to be death within 28 days of infection. Therefore,
we examined published literature for reports of B. pseudomallei
strains being used to experimentally infect animals. The strain
reference panel is to be used to test the efficacy of MCMs against
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Table 2 | Burkholderia pseudomallei strains that may be obtained
with low passage number.
Bacterial strain Passages from isolation Minimum passage score
DL2 6 4
DL25 6 4
DL28 6 4
DL35 6 4
DL36 6 4
INT2-BP127 6 4
INT2-BP190 6 4
INT2-BP24 6 4
INT2-BP270 6 4
INT2-BP38 6 4
INT2-BP91 6 4
INT4-BP18 6 4
MSHR296 6 4
MSHR305 6 4
MSHR487 6 4
MSHR503 6 4
MSHR520 6 4
MSHR668 6 4
MSHR730 6 4
MSHR840 6 4
NAU14B6 6 4
NAU21B9 6 4
NAU24B3 6 4
NAU33A4 6 4
NAU44A6 6 4
PB08298010 4 4
RF43-BP22 6 4
RF67-BP1 6 4
RF6-BP15 6 4
RF85-BP37 6 4
S141 6 4
S191 6 4
S241 6 4
S43 6 4
S90 6 4
INT2-BP48 6 4
inhalational melioidosis models, so emphasis was given to strains
shown to be virulent in inhalation animal models. Strains were
assigned a score on a scale of zero through five using the following
six criteria:
0 points for no data on animal infection
1 point for infection of animal cell cultures
2 points for animal infection indicated but no route of infection
reported
3 points for acute lethality in one or more mammals via a route
not intranasal (IN) or aerosol
4 points for acute lethality in one mammal with IN or aerosol
route
5 points for acute lethality in multiple mammals via IN or aerosol
route.
Table 3 | Burkholderia pseudomallei strains with animal models of
aerosol infection.
Bacterial
strain
LD50 (CFU) Animal
model
Reported animal
virulence data score
1026b 10 Mouse 5
27 Mouse
2.8×103 Mouse
DD503 1×103 Mouse 5
1.47×103 Mouse
103-67 16 Mouse 5
16 Hamster
W294 70 Hamster 5
K96243 5 Mouse 5
<10; precise LD50
not determined
Marmoset
Strains 1026b, DD503, 103-67, W294, and K96423 received the
highest score in this rating system (Table 3) and are discussed
below.
STRAIN 1026b
There is substantial literature on the virulence of B. pseudoma-
llei 1026b in animal models of melioidosis. In murine mod-
els of pneumonic melioidosis, Jeddeloh et al. (2003) exposed
BALB/c and C57BL/6 mice to whole-body aerosols. The LD50
of B. pseudomallei 1026b via this aerosol challenge method in
BALB/c and C57BL/6 mice was 10± 8 and 27± 20 colony-
forming units (CFU), respectively. The results suggest that both
mouse strains have similar susceptibilities to the aerosolized B.
pseudomallei. However, previous studies showed that the LD50
of IN challenge (an alternative to aerosol challenge) with 1026b
was 2 logs higher in the resistant C57BL6 mouse when com-
pared with the sensitive BALB/c mouse (Liu et al., 2002). Using
a nose-only inhalational challenge system we showed that the
LD50 in BALB/c mice was 2,772 CFUs (Sanford et al., 2010).
Goodyear et al. (2009) reported that the LD50 of an IN chal-
lenge in BALB/c mice was 1× 103 CFUs. These results sug-
gest that B. pseudomallei 1026b has an LD50 between 10 and
2,772 CFUs, depending on the route of infection and strain
of mouse infected. The difference in the LD50 for inhala-
tional melioidosis in BALB/c mice could reflect differences in
the method of aerosol challenge, whole-body, IN, or nose-
only and/or differences in the virulence of the 1026b strains
used in each of these studies and may be of interest in future
investigations.
STRAIN DD503
Strain DD503 (∆amrR-oprA) is a multi-drug efflux mutant
strain derived from 1026b, which is hypersensitive to aminogly-
cosides and macrolides (Moore et al., 1999). In a whole-body
inhalation BALB/c mouse model, the LD50 was determined to
be 1× 103 CFUs. Jeddeloh et al. (2003) reported the LD50 of
strain DD503 to be 1,467± 301 CFUs in BALB/c mice following
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Table 4 | Burkholderia pseudomallei strains with genome sequences.
Bacterial
strain
Whole genome sequenced data MLST
genotype
Genetic characterization
score
K96243 http://www.ncbi.nlm.nih.gov/nuccore/NC_006350 Yes 5
MSHR296 http://www.mggen.nau.edu/BurkNextGenProj/BurkNextGenProj.html Yes 5
MSHR840 http://www.mggen.nau.edu/BurkNextGenProj/BurkNextGenProj.html Yes 5
RF43-BP22 http://www.mggen.nau.edu/BurkNextGenProj/BurkNextGenProj.html Unknown 5
S191 P. Keim, personal communication ST315 5
1106a http://www.ncbi.nlm.nih.gov/nuccore/NC_009076 ST70 5
VN-Rat P. Keim, personal communication Unknown 5
1710b http://www.ncbi.nlm.nih.gov/nuccore/NC_007434 ST177 5
TGH P. Keim, personal communication Unknown 5
W294 P. Keim, personal communication Unknown 5
1106b http://www.ncbi.nlm.nih.gov/bioproject/54361 ST70 5
Pasteur 52237 http://www.ncbi.nlm.nih.gov/bioproject/54289 ST411 5
S13 http://www.ncbi.nlm.nih.gov/bioproject/54287 ST51 5
1655 http://www.ncbi.nlm.nih.gov/bioproject/54283 ST131 5
1710a http://www.ncbi.nlm.nih.gov/bioproject/54285 ST177 5
MSHR668 http://www.ncbi.nlm.nih.gov/genome/476?project_id=58389 ST129 5
406e http://www.ncbi.nlm.nih.gov/bioproject/54371 ST211 5
576 http://www.ncbi.nlm.nih.gov/bioproject/55425 ST501 5
MSHR346 http://www.ncbi.nlm.nih.gov/bioproject/55259 ST243 5
1026b http://www.ncbi.nlm.nih.gov/nuccore/385657254 and
http://www.ncbi.nlm.nih.gov/nuccore/CP002834
ST102 5
whole-body aerosol exposure. It is interesting that the mouse LD50
of DD503 is 100 times higher than 1026b. The reduced virulence of
DD503 appears to be due to a mutation in the rpsL gene (Jeddeloh
et al., 2003).
STRAIN 103-67
Dannenberg et al. (1958) challenged Syrian golden hamsters with
an inhaled dose 3–600 LD50S (50–10,000 CFUs), and the inhala-
tional LD50 of B. pseudomallei 103-67 in the hamster model
appears to be approximately 17 CFUs. The lethality of inhaled
B. pseudomallei strain 103-67 in albino mice was also examined,
and in mice that succumbed to infection with an inhaled does of
18–600 LD50s (300–10,000 CFUs), the inhalational LD50 in mice
of approximately 17 CFUs.
STRAIN W294
Miller et al. (1948) determined the virulence of IP challenges of B.
pseudomallei strain W294 in hamsters, guinea pigs, ferrets, rabbits,
mice, rats, and non-human primates. However, the aerosol LD50
of W294 was determined to be 70 CFU in the hamster. Black and
white mice were infected with B. pseudomallei W294 and 60–75%
of the animals died, but the LD50 was not evaluated.
STRAIN K96243
The vast majority of animal work done with strain K96243 was
performed in mice (C57Bl/6 and BALB/c). In an effort to examine
the differential susceptibility to infection between the two most
commonly used mouse strains (C57Bl/6 and BALB/c), Tan et al.
(2008) infected both mouse strains via various routes includ-
ing the IN (nose-only aerosol). The calculated IN LD50 was
226 CFU in BALB/c mice and 1.5× 104 CFU in C57Bl/6 mice.
Their data indicates that BALB/c mice are significantly more
susceptible to infection with B. pseudomallei than the C57Bl/6
strain.
While large animal models of infection with B. pseudomallei
have not yet been extensively examined, one recent study by Nel-
son et al. (2011) aimed to determine if the common marmoset
would be a viable large animal model of infection. A lethal infec-
tion was established with aerosol challenge doses below 10 CFU.
Because of the extreme lethality, a precise LD50 was not able to be
determined. They concluded that the common marmoset should
be considered as a suitable model for further studies of inhalational
melioidosis.
GENETIC CHARACTERIZATION
Burkholderia pseudomallei is a soil-dwelling saprophyte and with
genetic diversity resulting from horizontal gene transfer (Tuanyok
et al., 2008; Zhu et al., 2011). These transfers are recognized
as regions in the genome [genomic island (GI) regions] with
lower G/C content and that encode a broad array of functions.
Genetic variability has been demonstrated in strains isolated from
a single patient and isolates from different tissues within the
patient (Hayden et al., 2012). This genetic variability makes it
essential that the genomes of each strain in the panel be geneti-
cally characterized. B. pseudomallei strains have been genotyped
using PCR methods, such as random amplified polymorphic DNA
(RAPD; Leelayuwat et al., 2000) and multilocus sequence typing
(MLST; Godoy et al., 2003; McCombie et al., 2006). RAPD detects
differences in genomes by amplifying segments of unknown DNA.
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These PCR fragments are separated based upon electrophoretic
mobility and the strains are compared by the presence or absence
of bands. The production of PCR artifacts makes this genotyping
method less robust than MLST genotyping. MLST compares the
sequence of artificially concatenated amplicons of seven house-
keeping genes. These genes are assumed to be selectively neutral
or under purifying selection. MLST provides nucleotide data for
multiple haplotypes, is amenable to phylogenetic analyses. Currie
et al. (2007) reported that the MLST genotypes of strains from
Australia were distinct from strains isolated in Thailand. Another
PCR-based method variable number tandem repeat (VNTR) loci
has been shown as a useful tool for genotyping B. pseudomallei.
A VNTR locus consists of tandemly repeated sequences of DNA
that vary in copy number, creating PCR amplicon size polymor-
phisms that are easily detected with gel electrophoresis. Due to
increased mutation rates when compared to other regions of DNA
and their multi-allelic nature, VNTRs allow superior discrimina-
tion between closely related isolates. Variations in VNTR can be
observed in serially passed isolates (U’Ren et al., 2007; Price et al.,
2010).
Finally, the rapid reduction in the cost of whole genome
sequencing makes it feasible to compare the genomic sequence
of different strains and to identify any genetic changes occurring
due to in vitro or in vivo passage. Therefore, the scoring for genetic
characterization was:
0 points for no genetic data (note that there are no criteria under
which we assigned 1 or 2 points, given the importance of genetic
characterization)
3 points for MLST
4 points for sequencing of GIs
5 points for sequenced genome data.
Twenty strains received the highest score in this rating system
(Table 4) although a discussion of the features of the sequencing
efforts is beyond the scope of this review.
STRAIN AVAILABILITY
Because an overarching objective of our B. pseudomallei research is
to find common animal models that are acceptable to the FDA for
Animal Rule research, common, well-characterized strains would
ideally be made available to the B. pseudomallei research commu-
nity. Therefore, we reviewed the legal constraints for individual
B. pseudomallei strains in publicly available data and personnel
communications. Strains were assigned a score on a scale of zero
through five using the following six criteria. While the grading scale
used encompassed five through zero, no score of three was assigned
to increase the distinction between restricted and unrestricted
strains.
0 points for no information identified
1 point for license required for use or distribution
2 points for MTA required
4 points for strains available through a collaborator’s collection
without restriction
5 points for strains available in the public domain.
Table 5 | Burkholderia pseudomallei strains available in the public
domain.
Bacterial strain Availability Intellectual property score
9 Public domain 5
112 Public domain 5
576 Public domain 5
1026b Public domain 5
DD503 Public domain 5
DL2 Public domain 5
DL25 Public domain 5
DL28 Public domain 5
DL35 Public domain 5
DL36 Public domain 5
INT2-BP127 Public domain 5
INT2-BP190 Public domain 5
INT2-BP24 Public domain 5
INT2-BP270 Public domain 5
INT2-BP38 Public domain 5
INT2-BP91 Public domain 5
INT4-BP18 Public domain 5
K96243 Public domain 5
MSHR296 Public domain 5
MSHR305 Public domain 5
MSHR487 Public domain 5
MSHR503 Public domain 5
MSHR520 Public domain 5
MSHR644 Public domain 5
MSHR668 Public domain 5
MSHR730 Public domain 5
MSHR840 Public domain 5
NAU14B6 Public domain 5
NAU21B9 Public domain 5
NAU24B3 Public domain 5
NAU33A4 Public domain 5
NAU44A6 Public domain 5
NCTC 13178 Public domain 5
NCTC 13178(CL24) Public domain 5
NCTC 13179 Public domain 5
NCTC 13179(CL07) Public domain 5
Pasteur 52237 Public domain 5
PB08298010 Public domain 5
RF43-BP22 Public domain 5
RF67-BP1 Public domain 5
RF6-BP15 Public domain 5
RF85-BP37 Public domain 5
S141 Public domain 5
S191 Public domain 5
S241 Public domain 5
S43 Public domain 5
S90 Public domain 5
Many of the strains we investigated were available, and we iden-
tified 52 strains available in the public domain as listed in Table 5.
Further discussion of availability of strains is beyond the scope of
this review.
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PANEL SELECTION AND DISCUSSION
With the overall objective of creating a panel of well-characterized
B. pseudomallei strains for use in animal model development, we
totaled the scores for strain source, passage history, virulence,
genotype, phenotype, and availability for each strain. We then
selected the six strains with the highest scores to develop into
a panel of B. pseudomallei reference strains, with the intention
of using these strains to develop animal models (Table 6). The
selected strains were 1026b, MSHR668, K96243, MSHR305, 1106a,
and 406e. MSHR668 was isolated from a human encephalomyelitis
case. Strain 1026b has been used extensively in animal infection
models of melioidosis, is available in the public domain, and
has a published annotated genome sequence. Furthermore, 1026b
was isolated from a human case without pulmonary involvement.
However, a low passage stock of 1026b was not located. Nonethe-
less, the extensive animal research conducted with 1026b as well
as an annotated genome sequence makes it a good choice for the
reference panel. While it was not isolated from a pulmonary pre-
sentation case and had no animal virulence data, the relatively
low passage number, availability of genome sequence data, and
availability to laboratories made MSHR668 a good choice for the
reference panel. Strain K96243 is a well-studied laboratory strain
of B. pseudomallei isolated from a human case. While this strain
was not isolated from a pulmonary case and had an unknown
passage history, it has sequence data and extensive mouse vir-
ulence data, including studies indicating a very low LD50. In
addition, K96243 is readily available, making it a good choice for
a panel of B. pseudomallei strains for animal models of melioido-
sis. MSHR305 was also isolated from a human encephalomyelitis
case, but with low passage, MLST data and some animal viru-
lence data in mice, this strain also may prove useful in animal
models of melioidosis. Strain 1106a was isolated from a human
case but details on pulmonary presentation were not available.
However, the 1106a genome is sequenced and the intratracheal
infection of rats resulted in a lethal disease. Furthermore, a low
passage isolate could be obtained, making 1106a a good candidate
for inclusion on the panel. Finally, 406e was isolated from a human
case with pulmonary involvement, genome sequence data, a low
LD50 in intraperitoneal infection of hamsters and the availability
of a relatively low passage isolate made 406e the highest scoring B.
pseudomallei strain in our literature review and a very good candi-
date for inclusion in a panel of reference strains for animal models
of melioidosis. With these data, it is our intention to develop a set
of cell banks to serve as a reference panel of B. pseudomallei strains
for use in animal models of melioidosis.
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